|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase IV
|
|
|
|
Biomarker/Laboratory analysis, Treatment
|
|
|
|
Active
|
|
|
|
18 and under
|
|
|
|
NICHD
|
|
|
|
PPRU 10762 NCT00491946
|
|
|
|
|
|
|
|
Last Modified: 4/21/2008  First Published: 8/24/2003 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II, Phase I
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
Any age
|
|
|
|
NCI
|
|
|
|
FHCRC-1803.00 NCT00068718
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II, Phase I
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
21 and under
|
|
|
|
Other
|
|
|
|
BMT 0499 Solid NCT00179816
|
|
|
|
|
|
|
|
Last Modified: 8/23/2008  First Published: 7/1/2001 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
18 and over
|
|
|
|
Other
|
|
|
|
WSU-2007-033 NCT00020722, RWMC-0634246
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
21 and under
|
|
|
|
Other
|
|
|
|
UMCC 9626 IRB 1996-195, NCT00141765
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
30 and under
|
|
|
|
Other
|
|
|
|
UMCC 2005.050 GCRC ID # 2191, NCT00405327
|
|
|
|
|
|
|
|
Last Modified: 9/3/2008  First Published: 2/14/2008 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
Not specified
|
|
|
|
NCI
|
|
|
|
UMN-2007LS072 UMN-2007LS072, UMN-MT2007-07, NCT00617929
|
|
|
|
|
|
|
|
Last Modified: 12/10/2007  First Published: 1/1/2002 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase I
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
2 to 21
|
|
|
|
NCI
|
|
|
|
NCI-02-C-0031E 02-C-0031, 5425, NCI-5425, NCT00030108
|
|
|
|
|
|
|
|
Last Modified: 2/11/2008  First Published: 7/7/2006 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase I
|
|
|
|
Biomarker/Laboratory analysis, Treatment
|
|
|
|
Active
|
|
|
|
2 to 18
|
|
|
|
NCI, Pharmaceutical / Industry
|
|
|
|
NCI-06-C-0152 NCI-P6571, NCT00354848, ZENECA-D8480C00016
|
|
|
|
|
|
|
|
Last Modified: 7/10/2007  First Published: 1/19/2007 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase I
|
|
|
|
Biomarker/Laboratory analysis, Treatment
|
|
|
|
Active
|
|
|
|
1 to 21
|
|
|
|
NCI
|
|
|
|
NCI-07-C-0040 NCI-P6981, NCT00428272
|
|
|
|